Abstract 425P
Background
Personalized neoantigen peptide-based therapeutic cancer vaccines, designed to trigger de novo T cell responses against neoantigens, are always considered safe and highly specific to tumours of individual patients, which can amplify and broaden the endogenous repertoire of tumour-specific T cells. However, naked peptide vaccines are often faced with significant challenges such as early enzymatic degradation, poor antigen presentation by dendritic cells (DCs), tumour low immunogenicity, and limited lymph nodes (LNs) trafficking. Therefore, an effective tumour vaccine vector which can rapidly display peptides and promote antigen cross-presentation is urgently needed. Compared with other biomaterials such as Montanide ISA-51 and injectable hydrogels, probiotics which participate in human health dynamically and closely can be utilized as a promising delivery system with the integration of synthetic biology and chemical biotechnology.
Methods
We developed a probiotic food-grade Lactococcus lactis-based in situ vaccination (FOLactis) expressing a fusion protein of Fms-like tyrosine kinase 3 ligand and co-stimulator OX40 ligand, physically attaching neoantigen peptides onto the FOLactis cell wall (Ag-FOLactis) by using a cell penetrating peptide sequence derived from human immunodeficiency virus Tat N-terminally. The in vivo metabolism and biodistribution of Ag-FOLactis was explored using near infrared living imaging. We also checked the neoantigen-reactive T cell response in vivo and ex vivo by flow cytometry.
Results
Ag-FOLactis can keep in the injection site, slow the degradation of peptides and attract DCs to present antigens. In multiple tumour-bearing mouse models, locoregional administration of Ag-FOLactis in lymph nodes significantly triggers tumour-specific T cell response, inhibits tumour growth and prolongs the survival of tumour-bearing mice. Ag-FOLactis also synergizes with an anti-PD1 antibody.
Conclusions
Overall, we find that Ag-FOLactis represents a flexible and powerful personalized cancer vaccine platform for displaying different neoantigen peptides, with enhanced specific anti-tumour immunity and little harm to important organs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract